Non-Alcoholic Steatohepatitis (NASH) Market USD 4.57 Billion in 2022

The global non-alcoholic steatohepatitis (NASH) market was valued at USD 4.57 Billion in 2022 and is projected to reach USD 180.09 Billion by 2030, growing at a CAGR of 58.64%from 2022 to 2030. Non-alcoholic steatohepatitis (NASH) is a medical condition in which there is inflammation, as well as damage in the liver caused by the accumulation of fat around the liver. It is part of a group of conditions called NAFLD (non-alcoholic fatty liver disease).  Non-alcoholic steatohepatitis (NASH) can get worse and cause scarring of the liver, which leads to cirrhosis. It shows similarity to a kind of liver disorder that is caused by long-term abuse of alcohol. However, it is found in people who drink little or no alcohol.

Obesity, high cholesterol, high triglycerides, metabolic syndrome, insulin resistance, and type 2 diabetes are some of the key factors that can trigger or increase the risk of NASH and liver damage.  Increasing prevalence of obesity and diabetes in developed as well as developing economies on account of a sedentary lifestyle, increased calorie intake associated with consumption of processed food, and alcoholism is likely to provide impetus to non-alcoholic steatohepatitis (NASH) market growth.

Around 26% of the world’s population suffers from hypertension, and the prevalence is estimated to increase to 29% by the end of 2025. The high prevalence of hypertension is leading to tremendous public health burden and is majorly driven rise in economically developing nations. In 2016, over 1.6 million deaths were directly caused by diabetes, and the WHO estimates diabetes to be the seventh leading cause of death in the same year. Apart from diabetes and hypertension, the prevalence of dyslipidemia (high blood lipid) will also create a lucrative scope for NASH industry expansion.

Request a Sample@

The WHO estimates that dyslipidemia is linked with over half of global cases of ischemic heart disease and liver disorders. Over the past decades, researches have consistently shown the burden of dyslipidemia to be extremely high in terms of medical costs, morbidity, and mortality. Rising incidence of dyslipidemia, hypertension, Type 2 diabetes, obesity, and diabetes globally and associated rise in NASH mortalities will boost industry forecast.

Regional landscape

North America’s non-alcoholic steatohepatitis (NASH) market is estimated to showcase a CAGR of 53% over the analysis period. As per recent statistics, the incidence rate of NAFLD in the U.S. is around 25%, out of which non-alcoholic steatohepatitis (NASH) accounts for 3-8%. The growing prevalence of diseases in the region is creating favorable growth opportunities for drugmakers. Key regional manufacturers in the industry are investing in R&D activities to boost the development of novel drugs for non-alcoholic steatohepatitis (NASH)treatment.


  • The non-alcoholic steatohepatitis (NASH) market registered an impressive growth rate in recent years, a trend that is expected to continue over 2022-2027.
  • Increasing adoption of sedentary lifestyles and the consumption of processed food and alcohol among the global populace are leading to several health conditions.
  • The global prevalence of dyslipidemia, Type 2 diabetes, hypertension, obesity, and heart diseases are the key factors contributing to the rise in non-alcoholic steatohepatitis (NASH) mortalities.
  • North America’s non-alcoholic steatohepatitis (NASH) market is estimated to grow at a CAGR of 53% over 2022-2027.
  • The incidence rate of NAFLD in the U.S. is around 25%, out of which NASH accounts for 3-8%.
  • The increasing involvement of market players in R&D activities, along with collaborative deals with other players for the development of novel drugs for treatment, will boost business growth. Under a recent licensing agreement for a drug developed for non-alcoholic steatohepatitis (NASH), Korean drug maker Hanmi Pharmaceutical may receive over USD 800 million from Merck & Co.

Competitive landscape

Several key manufacturers, including Genfit, Gilead Sciences, and others, are focusing on bringing forth effective non-alcoholic steatohepatitis (NASH) treatment. For instance, the Food & Drug Administration has accepted a new drug application by Intercept Pharmaceuticals for the treatment of liver fibrosis caused by non-alcoholic steatohepatitis (NASH). Intercept also announced that obeticholic acid (OCA), under the Ocaliva brand, has already been approved for the treatment of primary biliary cholangitis/ cirrhosis (an autoimmune liver disease) and has a PDUFA (Prescription Drug User Fee Act) date. The company claimed that if OCA is approved, it would be the first therapy available for the treatment of fibrosis due to non-alcoholic steatohepatitis, a condition that is estimated to become one of the major causes of liver transplant in the United States by the end of 2022.

New reports project that it is likely that obeticholic acid can reduce progression to cirrhosis and improve certain outcomes in patients over the long term. However, the magnitude of its advantages and side-effects is uncertain.

Deal landscape

Currently, there are no approved drugs for the treatment of non-alcoholic steatohepatitis (NASH), but several companies are adopting organic and inorganic strategies to develop novel drugs. For instance, on 4th August 2022, US-based Merck & Co. entered a licensing agreement with Hanmi Pharmaceutical, a Seoul-based pharmaceutical firm that is into the commercialization of a GLP-1/glucagon receptor dual agonist, efinopegdutide, developed for the treatment of non-alcoholic steatohepatitis (NASH). Under the licensing agreement for drugs developed for NASH, the Korean drugmaker may receive over USD 800 million from Merck & Co. The rise in investments in R&D activities and drug development, along with the increased focus of industry players on growth strategies, will create favorable conditions for industry expansion over the analysis period.

Companies profiled

The non-alcoholic steatohepatitis (NASH) companies profiled in the report are Genfit, Gilead Sciences, Intercept Pharmaceuticals, Inventiva, Galmed Pharmaceuticals, Tobira Therapeutics, and Allergan.

Segments covered in the report:

This report forecasts revenue growth at a global, regional, and country-level while providing an analysis of the industry trends of the sub-segments from 2022-2030. For the purpose of the study, Reports and data have segmented the Global Non-Alcoholic Steatohepatitis (NASH) Market on the basis of disease cause, drug type, end-user, and region:

Disease cause (Revenue USD Million; 2022-2030)

  • Hypertension
  • Heart Disease
  • High blood Lipid
  • Type 2 diabetes
  • Obesity

Drug Type (Revenue, USD Million, 2022-2030)

  • Vitamin E & Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cencicriviroc
  • Others

End-user Outlook (Revenue, USD; 2022-2030)

  • Hospitals
  • Clinics
  • Homecare Settings

Regional Outlook (Revenue, USD Million; 2022-2030)

  • North America
    • U.S
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • China
    • India
    • Southeast Asia
  • Latin America
    • Brazil
  • Middle East & Africa

Buy quantitative research Report at discounted price – USD 1500

You can place an order or ask any questions, please feel free to contact [email protected] | +1 9197 992 333



About Us

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.

For Latest Update Follow Us:


Leave a Comment

Your email address will not be published. Required fields are marked *